HEIDELBERG UNIVERSITY

European Consortium Secures €2.5 Million to Develop Predictive Biomarker Test for Immunotherapy Response

7 days ago

• A European consortium led by OncoHost has been awarded €2.5 million from the EIC Transition Programme to develop NeutroFlow, a diagnostic test predicting patient response to immune checkpoint inhibitors across five cancer types. • The point-of-care test leverages breakthrough research on Ly6Ehi neutrophils as predictive biomarkers and will use flow cytometry technology deployable in standard hospital settings. • The collaborative project involves prestigious institutions including Heidelberg University Hospital, European Institute of Oncology, and Virgen Macarena University Hospital, with activities launching in May 2025.

Isatuximab Combinations Show Promise in Newly Diagnosed Multiple Myeloma

6 months ago

• Isatuximab plus VRd significantly reduced disease progression or death risk by 40.4% in transplant-ineligible newly diagnosed multiple myeloma patients. • The FDA approved isatuximab-irfc with VRd for transplant-ineligible multiple myeloma, based on the IMROZ trial data. • Isatuximab-RVd induction therapy improved progression-free survival in transplant-eligible newly diagnosed multiple myeloma patients, GMMG-HD7 trial showed. • The addition of isatuximab to RVd led to higher rates of minimal residual disease negativity, indicating deeper responses.